Kristen Nowak
Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polycystic Kidney, Autosomal Dominant | 20 | 2024 | 209 | 10.000 |
Why?
| Renal Insufficiency, Chronic | 23 | 2024 | 486 | 5.330 |
Why?
| Vascular Stiffness | 11 | 2023 | 407 | 3.690 |
Why?
| Endothelium, Vascular | 16 | 2021 | 843 | 2.700 |
Why?
| Blood Pressure | 14 | 2023 | 1538 | 2.300 |
Why?
| Glomerular Filtration Rate | 10 | 2024 | 604 | 2.070 |
Why?
| Kidney Failure, Chronic | 9 | 2020 | 489 | 2.040 |
Why?
| Kidney | 11 | 2024 | 1187 | 2.010 |
Why?
| Caloric Restriction | 3 | 2024 | 90 | 1.710 |
Why?
| Sodium, Dietary | 3 | 2023 | 36 | 1.640 |
Why?
| Hypertension | 7 | 2021 | 1056 | 1.470 |
Why?
| Vascular Diseases | 4 | 2021 | 230 | 1.460 |
Why?
| Blood Vessels | 4 | 2024 | 180 | 1.460 |
Why?
| Sodium | 3 | 2019 | 183 | 1.400 |
Why?
| Diet, Sodium-Restricted | 4 | 2020 | 34 | 1.280 |
Why?
| Disease Progression | 9 | 2024 | 2380 | 1.230 |
Why?
| Cardiovascular Diseases | 12 | 2023 | 1727 | 1.080 |
Why?
| Oxidative Stress | 11 | 2024 | 1076 | 1.050 |
Why?
| Renal Dialysis | 5 | 2019 | 374 | 0.970 |
Why?
| Interleukin-1 | 3 | 2019 | 966 | 0.940 |
Why?
| Brachial Artery | 9 | 2018 | 176 | 0.940 |
Why?
| Lipocalin-2 | 2 | 2024 | 61 | 0.940 |
Why?
| Recombinant Fusion Proteins | 2 | 2017 | 616 | 0.920 |
Why?
| Kidney Tubules | 1 | 2024 | 107 | 0.880 |
Why?
| Cognitive Dysfunction | 2 | 2018 | 284 | 0.880 |
Why?
| Intra-Abdominal Fat | 1 | 2024 | 77 | 0.880 |
Why?
| Metformin | 2 | 2024 | 276 | 0.880 |
Why?
| Aging | 8 | 2018 | 1618 | 0.880 |
Why?
| Cognition | 3 | 2023 | 988 | 0.860 |
Why?
| Inflammation | 8 | 2020 | 2477 | 0.850 |
Why?
| Pulse Wave Analysis | 8 | 2023 | 207 | 0.830 |
Why?
| Middle Aged | 38 | 2024 | 26719 | 0.810 |
Why?
| Humans | 72 | 2024 | 114616 | 0.790 |
Why?
| Endothelial Cells | 4 | 2023 | 681 | 0.780 |
Why?
| Fibroblast Growth Factors | 3 | 2019 | 162 | 0.780 |
Why?
| Curcumin | 1 | 2021 | 28 | 0.760 |
Why?
| Male | 50 | 2024 | 55549 | 0.760 |
Why?
| Aged | 30 | 2023 | 19061 | 0.760 |
Why?
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 11 | 0.740 |
Why?
| Biomarkers | 7 | 2024 | 3405 | 0.720 |
Why?
| Double-Blind Method | 11 | 2023 | 1660 | 0.710 |
Why?
| Dementia | 1 | 2023 | 187 | 0.710 |
Why?
| Renal Agents | 1 | 2020 | 5 | 0.700 |
Why?
| Systole | 1 | 2020 | 171 | 0.690 |
Why?
| Overweight | 2 | 2021 | 471 | 0.680 |
Why?
| Female | 45 | 2024 | 59461 | 0.670 |
Why?
| Polycystic Kidney Diseases | 1 | 2019 | 55 | 0.650 |
Why?
| Kidney Neoplasms | 1 | 2023 | 327 | 0.650 |
Why?
| Vasodilation | 7 | 2017 | 419 | 0.640 |
Why?
| Spironolactone | 1 | 2019 | 28 | 0.640 |
Why?
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 38 | 0.630 |
Why?
| Potassium, Dietary | 1 | 2018 | 10 | 0.600 |
Why?
| Drinking Water | 1 | 2019 | 64 | 0.600 |
Why?
| Interleukin-6 | 2 | 2020 | 676 | 0.590 |
Why?
| Hyponatremia | 1 | 2018 | 37 | 0.590 |
Why?
| Healthy Lifestyle | 1 | 2018 | 29 | 0.590 |
Why?
| Autophagy | 1 | 2019 | 233 | 0.580 |
Why?
| Primary Prevention | 2 | 2018 | 172 | 0.570 |
Why?
| Death | 1 | 2018 | 107 | 0.570 |
Why?
| Obesity | 2 | 2021 | 2507 | 0.570 |
Why?
| Adult | 25 | 2024 | 30528 | 0.530 |
Why?
| Energy Metabolism | 2 | 2024 | 731 | 0.520 |
Why?
| Vitamin D | 5 | 2018 | 341 | 0.500 |
Why?
| Atherosclerosis | 2 | 2018 | 341 | 0.500 |
Why?
| Bacterial Infections | 1 | 2016 | 218 | 0.480 |
Why?
| Longitudinal Studies | 5 | 2018 | 2387 | 0.450 |
Why?
| Hypercapnia | 2 | 2023 | 51 | 0.420 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2024 | 35 | 0.410 |
Why?
| Young Adult | 12 | 2024 | 10455 | 0.380 |
Why?
| Sodium Chloride, Dietary | 2 | 2023 | 30 | 0.380 |
Why?
| Time Factors | 7 | 2021 | 6112 | 0.370 |
Why?
| Apoptosis | 1 | 2019 | 2362 | 0.360 |
Why?
| Carotid Arteries | 3 | 2018 | 180 | 0.360 |
Why?
| Regional Blood Flow | 7 | 2016 | 424 | 0.350 |
Why?
| Vascular Calcification | 2 | 2018 | 107 | 0.330 |
Why?
| Cardiovascular System | 2 | 2023 | 125 | 0.330 |
Why?
| Uric Acid | 2 | 2018 | 148 | 0.330 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 373 | 0.320 |
Why?
| Prospective Studies | 9 | 2023 | 6214 | 0.320 |
Why?
| TRPP Cation Channels | 2 | 2020 | 63 | 0.320 |
Why?
| Cerebrovascular Circulation | 2 | 2023 | 221 | 0.310 |
Why?
| Cohort Studies | 5 | 2024 | 4894 | 0.300 |
Why?
| Hospitalization | 1 | 2016 | 1749 | 0.300 |
Why?
| NF-kappa B | 4 | 2015 | 638 | 0.290 |
Why?
| Energy Intake | 2 | 2020 | 427 | 0.280 |
Why?
| Independent Living | 2 | 2018 | 84 | 0.280 |
Why?
| Cross-Sectional Studies | 5 | 2024 | 4405 | 0.280 |
Why?
| Femoral Artery | 2 | 2018 | 167 | 0.270 |
Why?
| Phosphates | 2 | 2024 | 159 | 0.270 |
Why?
| Risk Factors | 8 | 2022 | 8628 | 0.270 |
Why?
| Brain | 1 | 2018 | 2371 | 0.270 |
Why?
| Organ Size | 2 | 2017 | 434 | 0.260 |
Why?
| Exercise | 4 | 2018 | 1644 | 0.260 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2015 | 76 | 0.250 |
Why?
| Magnetic Resonance Imaging | 3 | 2024 | 3039 | 0.240 |
Why?
| Kaplan-Meier Estimate | 2 | 2018 | 811 | 0.240 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 179 | 0.240 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2024 | 17 | 0.240 |
Why?
| Lanthanum | 1 | 2024 | 8 | 0.240 |
Why?
| Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 8 | 0.230 |
Why?
| Transcription Factor CHOP | 1 | 2014 | 28 | 0.230 |
Why?
| Potassium | 1 | 2014 | 128 | 0.230 |
Why?
| Genotype | 2 | 2020 | 1760 | 0.230 |
Why?
| Physical Fitness | 2 | 2013 | 179 | 0.230 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2024 | 60 | 0.230 |
Why?
| Chemokine CCL2 | 1 | 2024 | 105 | 0.230 |
Why?
| Minerals | 2 | 2019 | 37 | 0.230 |
Why?
| Obesity, Abdominal | 1 | 2024 | 37 | 0.230 |
Why?
| Body Mass Index | 2 | 2024 | 1956 | 0.220 |
Why?
| Blood Flow Velocity | 2 | 2023 | 387 | 0.220 |
Why?
| Bufanolides | 1 | 2013 | 4 | 0.220 |
Why?
| Diet, Ketogenic | 1 | 2023 | 33 | 0.220 |
Why?
| Blood Glucose | 2 | 2021 | 1819 | 0.220 |
Why?
| Glycosphingolipids | 1 | 2023 | 8 | 0.220 |
Why?
| Adolescent | 7 | 2021 | 17830 | 0.210 |
Why?
| Pneumonia, Bacterial | 1 | 2014 | 106 | 0.210 |
Why?
| Cystatin C | 1 | 2013 | 62 | 0.210 |
Why?
| Reactive Oxygen Species | 2 | 2023 | 531 | 0.210 |
Why?
| Sodium Bicarbonate | 2 | 2023 | 40 | 0.210 |
Why?
| Community-Acquired Infections | 1 | 2014 | 141 | 0.210 |
Why?
| Treatment Outcome | 6 | 2020 | 9084 | 0.200 |
Why?
| Endoplasmic Reticulum | 1 | 2014 | 234 | 0.200 |
Why?
| Calcinosis | 1 | 2014 | 242 | 0.200 |
Why?
| Creatinine | 1 | 2013 | 425 | 0.190 |
Why?
| Forearm | 2 | 2009 | 112 | 0.190 |
Why?
| Follow-Up Studies | 3 | 2019 | 4411 | 0.180 |
Why?
| Retrospective Studies | 4 | 2024 | 12542 | 0.180 |
Why?
| Child | 5 | 2023 | 18402 | 0.180 |
Why?
| Cytokines | 2 | 2018 | 1840 | 0.180 |
Why?
| Endothelin-1 | 2 | 2009 | 167 | 0.180 |
Why?
| Weight Loss | 1 | 2015 | 641 | 0.180 |
Why?
| Parathyroid Hormone | 2 | 2018 | 96 | 0.180 |
Why?
| Allopurinol | 2 | 2018 | 53 | 0.180 |
Why?
| Euthyroid Sick Syndromes | 1 | 2020 | 1 | 0.180 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2021 | 1214 | 0.170 |
Why?
| Salicylates | 2 | 2015 | 30 | 0.170 |
Why?
| Nutritive Value | 1 | 2020 | 30 | 0.170 |
Why?
| C-Reactive Protein | 2 | 2018 | 362 | 0.170 |
Why?
| Caspase Inhibitors | 1 | 2019 | 78 | 0.170 |
Why?
| Adiposity | 1 | 2024 | 457 | 0.170 |
Why?
| Bangladesh | 1 | 2019 | 31 | 0.160 |
Why?
| Salinity | 1 | 2019 | 18 | 0.160 |
Why?
| Drinking | 1 | 2019 | 33 | 0.160 |
Why?
| Animals | 6 | 2023 | 31692 | 0.160 |
Why?
| Patient Advocacy | 1 | 2019 | 66 | 0.160 |
Why?
| Lipoproteins, HDL | 1 | 2019 | 75 | 0.160 |
Why?
| Vitamin D Deficiency | 1 | 2010 | 158 | 0.160 |
Why?
| Cross-Over Studies | 4 | 2018 | 440 | 0.160 |
Why?
| Caspases | 1 | 2019 | 245 | 0.160 |
Why?
| Carotid Intima-Media Thickness | 1 | 2018 | 65 | 0.150 |
Why?
| Sepsis | 1 | 2014 | 509 | 0.150 |
Why?
| Inflammation Mediators | 2 | 2017 | 477 | 0.150 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2009 | 184 | 0.150 |
Why?
| Enteral Nutrition | 1 | 2020 | 159 | 0.150 |
Why?
| Case-Control Studies | 3 | 2016 | 3001 | 0.150 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 41 | 0.150 |
Why?
| I-kappa B Proteins | 1 | 2008 | 79 | 0.150 |
Why?
| Dietary Supplements | 2 | 2017 | 460 | 0.150 |
Why?
| Healthy Aging | 1 | 2018 | 18 | 0.150 |
Why?
| Fathers | 1 | 2018 | 45 | 0.150 |
Why?
| Critical Illness | 2 | 2020 | 644 | 0.150 |
Why?
| Free Radical Scavengers | 1 | 2007 | 78 | 0.150 |
Why?
| Acidosis | 1 | 2018 | 88 | 0.140 |
Why?
| Intensive Care Units | 1 | 2021 | 617 | 0.140 |
Why?
| Pain | 1 | 2023 | 705 | 0.140 |
Why?
| Cholecalciferol | 1 | 2017 | 47 | 0.140 |
Why?
| Pilot Projects | 4 | 2024 | 1372 | 0.140 |
Why?
| Calcitriol | 1 | 2017 | 53 | 0.140 |
Why?
| Health Status | 1 | 2012 | 722 | 0.140 |
Why?
| Ascorbic Acid | 1 | 2007 | 110 | 0.140 |
Why?
| Enzyme Inhibitors | 2 | 2016 | 750 | 0.140 |
Why?
| Hypoglycemic Agents | 1 | 2024 | 1008 | 0.140 |
Why?
| Hyperuricemia | 1 | 2016 | 43 | 0.130 |
Why?
| Immunity, Humoral | 1 | 2017 | 112 | 0.130 |
Why?
| Chronic Disease | 2 | 2019 | 1578 | 0.130 |
Why?
| Vasoconstriction | 1 | 2007 | 177 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 663 | 0.130 |
Why?
| Signal Transduction | 2 | 2019 | 4509 | 0.130 |
Why?
| Severity of Illness Index | 3 | 2018 | 2537 | 0.130 |
Why?
| Up-Regulation | 1 | 2019 | 807 | 0.130 |
Why?
| Leg | 1 | 2007 | 225 | 0.130 |
Why?
| Neuroimaging | 1 | 2018 | 249 | 0.130 |
Why?
| Program Development | 1 | 2018 | 341 | 0.130 |
Why?
| Family | 1 | 2019 | 589 | 0.130 |
Why?
| Cell Nucleus | 1 | 2008 | 554 | 0.130 |
Why?
| Immunity, Cellular | 1 | 2017 | 248 | 0.130 |
Why?
| Communicable Diseases | 1 | 2017 | 129 | 0.130 |
Why?
| Nutritional Status | 1 | 2018 | 287 | 0.130 |
Why?
| Peripheral Arterial Disease | 1 | 2021 | 380 | 0.130 |
Why?
| Risk Assessment | 3 | 2021 | 2967 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 4 | 2012 | 1842 | 0.120 |
Why?
| Myocardial Infarction | 1 | 2022 | 927 | 0.120 |
Why?
| Patient Care Team | 1 | 2019 | 517 | 0.120 |
Why?
| Acute Kidney Injury | 1 | 2021 | 637 | 0.120 |
Why?
| Age of Onset | 1 | 2016 | 445 | 0.120 |
Why?
| Prenatal Diagnosis | 1 | 2016 | 167 | 0.120 |
Why?
| Antibodies, Monoclonal | 1 | 2020 | 1262 | 0.120 |
Why?
| Prognosis | 2 | 2021 | 3328 | 0.110 |
Why?
| Communication | 1 | 2019 | 744 | 0.110 |
Why?
| Survival Rate | 1 | 2018 | 1644 | 0.110 |
Why?
| Neuropsychological Tests | 1 | 2018 | 927 | 0.110 |
Why?
| Program Evaluation | 1 | 2018 | 822 | 0.110 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 299 | 0.110 |
Why?
| Sex Factors | 1 | 2018 | 1715 | 0.100 |
Why?
| United States | 2 | 2019 | 12176 | 0.100 |
Why?
| NADPH Oxidases | 2 | 2013 | 120 | 0.100 |
Why?
| Mothers | 1 | 2018 | 651 | 0.100 |
Why?
| Drug Therapy, Combination | 2 | 2015 | 951 | 0.100 |
Why?
| Fasting | 2 | 2023 | 240 | 0.100 |
Why?
| Prevalence | 1 | 2018 | 2249 | 0.100 |
Why?
| Physicians | 1 | 2019 | 772 | 0.090 |
Why?
| Quality of Life | 1 | 2012 | 2353 | 0.090 |
Why?
| Aged, 80 and over | 2 | 2019 | 6344 | 0.090 |
Why?
| Mutation | 1 | 2020 | 3344 | 0.090 |
Why?
| Lipoproteins, LDL | 2 | 2012 | 128 | 0.080 |
Why?
| Vascular Resistance | 2 | 2012 | 337 | 0.080 |
Why?
| Aorta | 2 | 2015 | 386 | 0.070 |
Why?
| Age Factors | 3 | 2009 | 2894 | 0.070 |
Why?
| Vasodilator Agents | 2 | 2009 | 302 | 0.070 |
Why?
| Infant, Newborn | 1 | 2016 | 5040 | 0.060 |
Why?
| Nitric Oxide | 2 | 2011 | 822 | 0.060 |
Why?
| Ketocholesterols | 1 | 2014 | 8 | 0.060 |
Why?
| Ezetimibe | 1 | 2014 | 24 | 0.060 |
Why?
| Dilatation, Pathologic | 1 | 2014 | 55 | 0.060 |
Why?
| Azetidines | 1 | 2014 | 31 | 0.060 |
Why?
| Apolipoproteins E | 1 | 2014 | 80 | 0.060 |
Why?
| Simvastatin | 1 | 2014 | 59 | 0.060 |
Why?
| Pravastatin | 1 | 2023 | 28 | 0.060 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 89 | 0.060 |
Why?
| Infant | 1 | 2016 | 7954 | 0.050 |
Why?
| Cysts | 1 | 2024 | 93 | 0.050 |
Why?
| Bicarbonates | 1 | 2023 | 41 | 0.050 |
Why?
| Biological Availability | 1 | 2012 | 119 | 0.050 |
Why?
| Compliance | 1 | 2012 | 46 | 0.050 |
Why?
| Microcirculation | 1 | 2012 | 135 | 0.050 |
Why?
| Nutrition Surveys | 1 | 2023 | 224 | 0.050 |
Why?
| Meta-Analysis as Topic | 1 | 2012 | 158 | 0.050 |
Why?
| Odds Ratio | 1 | 2014 | 953 | 0.050 |
Why?
| Gonadal Steroid Hormones | 1 | 2022 | 124 | 0.050 |
Why?
| Leukocyte Count | 1 | 2022 | 293 | 0.050 |
Why?
| Colorado | 2 | 2017 | 4099 | 0.050 |
Why?
| Nitroglycerin | 1 | 2010 | 19 | 0.050 |
Why?
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 16 | 0.050 |
Why?
| Cholesterol, LDL | 1 | 2012 | 307 | 0.040 |
Why?
| Lipids | 1 | 2014 | 580 | 0.040 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.040 |
Why?
| Muscles | 1 | 2021 | 320 | 0.040 |
Why?
| Triiodothyronine, Reverse | 1 | 2020 | 2 | 0.040 |
Why?
| Lymphocytes | 1 | 2022 | 330 | 0.040 |
Why?
| Prediabetic State | 1 | 2013 | 219 | 0.040 |
Why?
| Superoxide Dismutase | 1 | 2012 | 305 | 0.040 |
Why?
| Triiodothyronine | 1 | 2020 | 42 | 0.040 |
Why?
| Thyroxine | 1 | 2020 | 56 | 0.040 |
Why?
| Chicago | 1 | 2019 | 45 | 0.040 |
Why?
| Thyrotropin | 1 | 2020 | 99 | 0.040 |
Why?
| Diet Records | 1 | 2009 | 76 | 0.040 |
Why?
| Testosterone | 1 | 2022 | 343 | 0.040 |
Why?
| Logistic Models | 1 | 2014 | 1840 | 0.040 |
Why?
| Receptor, Endothelin A | 1 | 2009 | 59 | 0.040 |
Why?
| Monocytes | 1 | 2022 | 502 | 0.040 |
Why?
| Sex Characteristics | 1 | 2023 | 640 | 0.040 |
Why?
| Sulfaphenazole | 1 | 2008 | 3 | 0.040 |
Why?
| NF-KappaB Inhibitor alpha | 1 | 2008 | 52 | 0.040 |
Why?
| Cytochrome P-450 CYP2C9 | 1 | 2008 | 17 | 0.040 |
Why?
| omega-N-Methylarginine | 1 | 2008 | 26 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 739 | 0.040 |
Why?
| Nitroprusside | 1 | 2008 | 64 | 0.040 |
Why?
| Databases, Factual | 1 | 2013 | 1124 | 0.040 |
Why?
| Professional-Family Relations | 1 | 2019 | 133 | 0.040 |
Why?
| Mice, Knockout | 1 | 2014 | 2565 | 0.040 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 144 | 0.040 |
Why?
| Acetylcholine | 1 | 2008 | 166 | 0.040 |
Why?
| Ultrasonography, Doppler, Duplex | 1 | 2007 | 39 | 0.040 |
Why?
| Calcium | 1 | 2013 | 1104 | 0.040 |
Why?
| Nitric Oxide Synthase | 1 | 2008 | 209 | 0.040 |
Why?
| Regression Analysis | 1 | 2020 | 944 | 0.040 |
Why?
| Cholesterol | 1 | 2019 | 367 | 0.040 |
Why?
| Arteries | 1 | 2009 | 247 | 0.040 |
Why?
| Vasoconstrictor Agents | 1 | 2007 | 112 | 0.040 |
Why?
| Norepinephrine | 1 | 2007 | 201 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2007 | 371 | 0.030 |
Why?
| Epinephrine | 1 | 2007 | 163 | 0.030 |
Why?
| Reference Values | 1 | 2007 | 742 | 0.030 |
Why?
| Respiration, Artificial | 1 | 2020 | 529 | 0.030 |
Why?
| Incidence | 1 | 2021 | 2311 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2014 | 4689 | 0.030 |
Why?
| Phosphorylation | 1 | 2009 | 1569 | 0.030 |
Why?
| Acute Disease | 1 | 2017 | 910 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2019 | 1796 | 0.030 |
Why?
| Recovery of Function | 1 | 2017 | 574 | 0.030 |
Why?
| Insulin | 1 | 2013 | 2076 | 0.030 |
Why?
| Decision Making | 1 | 2019 | 782 | 0.030 |
Why?
| Heart Rate | 1 | 2015 | 709 | 0.020 |
Why?
| Mice | 1 | 2009 | 14859 | 0.010 |
Why?
|
|
Nowak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|